

PRECEPTORSHIP PROGRAMME

Gastrointestinal Tumours

Multidisciplinary management,
standards of care and future perspectives

SINGAPORE

20-22 NOVEMBER 2018

Co-Chairs Andrés Cervantes, ES
 Su Pin Choo, SG

ESMO PRECEPTORSHIP PROGRAMME GASTROINTESTINAL TUMOURS

Multidisciplinary management, standards of care and future perspectives

Singapore
20-22 November 2018

CO-CHAIRS:

Andrés Cervantes, Spain
Su Pin Choo, Singapore

SPEAKERS:

Chung Yip Chan, Singapore	Brigette Ma, Hong Kong
Ian Chau, United Kingdom	Sun Young Rha, South Korea
Cheng Ean Chee, Singapore	Jimmy B.-Y. So, Singapore
Min Hoe Chew, Singapore	Sho Suzuki, Japan
Fortunato Ciardiello, Italy	Josep Taberner, Spain
Claus-Henning Köhne, Germany	David Tai, Singapore
Tony Lim Kiat Hon, Singapore	Thomas Yau, Hong Kong

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, in special situations and side effects of treatments
- To learn about the management of unresectable/relapsing hepatocellular carcinoma and new approaches after failure of 1st line treatment
- To review the standard of care of anal carcinomas
- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment in gastric cancer
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **14 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Tuesday, 20 November 2018

09:00-09:15 15'	Welcome and introduction	Andrés Cervantes, ES Su Pin Choo, SG
09:15-10:55 100'	SESSION 1 Early colorectal cancer	Chair: Ian Chau, UK
40'	What pathology can tell us in the approach of localized colorectal cancer (including microsatellite instability and molecular aspects)	Tony Lim Kiat Hon, SG
20'	State-of-the-art: Standard of surgical practice for resectable rectal cancer	Min Hoe Chew, SG
20'	State-of-the-art: Standard of radio / chemotherapy for rectal cancer	Ian Chau, UK
20'	The role of adjuvant chemotherapy in localized rectal cancer	Andrés Cervantes, ES
10:55-11:15	Coffee break	
11:15-12:45 90'	SESSION 2 Adjuvant settings of colorectal cancer	Chair: Andrés Cervantes, ES
30'	A molecular classification for colorectal cancer: Current stages and future perspectives	Josep Taberero, ES
30'	Adjuvant treatment for colon cancer	Fortunato Ciardiello, IT
30'	Participants clinical case discussion (3x10')	Faculty
12:45-14:00	Lunch	
14:00-15:30 90'	SESSION 3 Metastatic colorectal cancer: Liver limited metastases	Chair: Chung Yip Chan, SG
30'	Review of the ESMO consensus conference on metastatic colorectal cancer	Fortunato Ciardiello, IT
30'	Advancements in surgery for colorectal liver metastases	Chung Yip Chan, SG
30'	Unresectable or borderline resectable chemotherapy +/- targeted agents	Claus-Henning Köhne, DE

Wednesday, 21 November 2018

08:30-09:45 75'	SESSION 4 Metastatic colorectal cancer I	Chair: Brigitte Ma, HK
50'	Chemotherapy and targeted agents in 1 st line	Brigitte Ma, HK
25'	The role of maintenance: Appropriate endpoints according to ESMO consensus	Claus-Henning Köhne, DE
09:45-10:55 70'	SESSION 5 Pancreatic and biliary tract cancer	Chair: Brigitte Ma, HK
40'	Medical treatment for pancreatic cancer (localized, locally advanced and metastatic)	Josep Taberero, ES
30'	Management of biliary tract cancer	David Tai, SG
10:55-11:15	Coffee break	

11:15-12:25 70'	SESSION 6 Hepatocellular Carcinoma (HCC)	Chair: Su Pin Choo, SG
20'	Management of intermediate HCC	Su Pin Choo, SG
20'	Update on medical treatment for unresectable HCC	Thomas Yau, HK
30'	Participants clinical case discussion (3x10')	Faculty
12:25-12:55 30'	SESSION 7 Anal tumours	Chair: Su Pin Choo, SG
30'	Standard of care for anal squamous carcinomas	Ian Chau, UK
12:55-14:00	Lunch	
14:00-15:20 80'	SESSION 8 Epidemiology, pathology and endoscopy of gastric cancer	Chair: Ian Chau, UK
20'	Epidemiology (including GE junction) and clinical presentation	Cheng Ean Chee, SG
30'	Endoscopy in gastric cancer: New imaging techniques and new treatment modalities (EMR, ESD)	Sho Suzuki, JP
30'	Surgery for gastric and GE junction cancer: Primary, palliative, where and when?	Jimmy B.-Y. So, SG
15:20-15:50	Coffee break	
15:50-17:00 70'	SESSION 9 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	Chair: Sun Young Rha, KR
40'	Neo- and adjuvant treatment for gastric cancer and GE junction cancer	Andrés Cervantes, ES
30'	Chemotherapy for metastatic disease	Sun Young Rha, KR
20:00	Dinner	

Thursday, 22 November 2018

09:00-11:50 140'	SESSION 10 Advanced disease	Chair: Sun Young Rha, KR
40'	Biological targeted agents (including HER2, EGFR, angiogenesis)	Sun Young Rha, KR
40'	Immunotherapy for advanced gastric cancer	Ian Chau, UK
10:20-10:50	Coffee break	
60'	Participants clinical case discussion (6x10')	Faculty
11:50-12:00 10'	Conclusion and farewell	Andrés Cervantes, ES Su Pin Choo, SG
12:00-13:00	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion